The CT revolution: the role of PIOPED II in establishing CT pulmonary angiography as the reference standard for pulmonary embolism diagnosis.
| Autor: | Pietersen PI; Department of Radiology, Odense University Hospital - Svendborg, Svendborg, Denmark.; UNIFY - Research and Innovation Unit of Radiology, University of Southern Denmark, Odense, Denmark., Goyard C; Department of Respiratory Diseases, Foch Hospital, Suresnes, France., Gille T; Inserm U1272 'Hypoxia and the Lung', UFR Santé - Médecine - Biologie Humaine Léonard de Vinci, Université Sorbonne Paris Nord, Bobigny, France.; Service de Physiologie et Explorations Fonctionnelles, Centre Hospitalier Universitaire Avicenne, Hôpitaux Universitaires de Paris Seine-Saint-Denis, Assistance Publique-Hôpitaux de Paris, Bobigny, France., de Margerie-Mellon C; Université Paris Cité, Department of Radiology, Hôpital Saint-Louis Assistance Publique-Hôpitaux de Paris, Paris, France., Falster C; Odense Respiratory Research Unit (ODIN), University of Southern Denmark, Odense, Denmark.; Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Breathe (Sheffield, England) [Breathe (Sheff)] 2024 Mar; Vol. 20 (1), pp. 230228. Date of Electronic Publication: 2024 Mar 12. |
| DOI: | 10.1183/20734735.0228-2023 |
| Abstrakt: | The PIOPED II study provided a robust estimate of the diagnostic accuracy of multidetector CTPA in suspected pulmonary embolism and played a pivotal role in establishing CTPA as the current diagnostic gold standard https://bit.ly/3HEyVxy. Competing Interests: Conflict of interest: P.I. Pietersen has received a travel grant from Boehringer Ingelheim. C. Goyard has no conflicts of interest to declare. T. Gille reports personal fees from Roche S.A.S., and other support from Oxyvie (oxygen provider), Vivisol France (oxygen provider), and Menaniri France outside the submitted work. C. de Margerie-Mellon has received fees from Bracco outside the submitted work. C. Falster has received personal fees from Bristol-Myers Squibb and AstraZeneca outside the submitted work. (Copyright ©ERS 2024.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|